We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+7.15%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$354M
AUM Growth
+$42.6M
Cap. Flow
+$21.7M
Cap. Flow %
6.13%
Top 10 Hldgs %
34.16%
Holding
110
New
22
Increased
38
Reduced
31
Closed
18

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$9.24M
2
TMO icon
Thermo Fisher Scientific
TMO
+$9.06M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$7.44M
4
XRAY icon
Dentsply Sirona
XRAY
+$6.15M
5
IRTC icon
iRhythm Holdings
IRTC
+$6.03M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$8.25M
2
VWR
VWR Corporation
VWR
+$7.23M
3
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$5.2M
4
WMGI
Wright Medical Group Inc
WMGI
+$4.63M
5
HOLX
Hologic
HOLX
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 88.14%
2 Financials 2.42%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
76
Regenxbio
RGNX
$620M
$711K 0.2%
36,000
+11,200
+45% +$217K
ARRY
77
DELISTED
Array Biopharma Inc
ARRY
$701K 0.2%
+83,700
New +$684K
LUMO
78
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$622K 0.18%
9,400
+2,795
+42% +$346K
BAX icon
79
Baxter International
BAX
$13.5B
$599K 0.17%
+9,900
New +$562K
DVAX
80
DELISTED
Dynavax Technologies
DVAX
$578K 0.16%
59,858
-113,600
-65% -$738K
BOLD
81
DELISTED
Audentes Therapeutics, Inc
BOLD
$559K 0.16%
+29,200
New +$466K
DPLO
82
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$522K 0.15%
35,243
-49,800
-59% -$830K
A icon
83
Agilent Technologies
A
$39.1B
$510K 0.14%
+8,600
New +$490K
ALDR
84
DELISTED
Alder Biopharmaceuticals
ALDR
$484K 0.14%
42,300
+5,600
+15% +$104K
EXEL icon
85
Exelixis
EXEL
$13.3B
$391K 0.11%
15,870
+6,000
+61% +$127K
CBIO
86
Crescent Biopharma
CBIO
$537M
$356K 0.1%
+319
New +$264K
ONCE
87
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$281K 0.08%
4,700
+700
+18% +$39.1K
LMNX
88
DELISTED
Luminex Corp
LMNX
$266K 0.08%
+12,600
New +$252K
XBI icon
89
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$255K 0.07%
3,300
-200
-6% -$14.2K
OCRX
90
DELISTED
Ocera Therapeutics, Inc.
OCRX
$140K 0.04%
120,942
-31,700
-21% -$36.8K
ANAB icon
91
AnaptysBio
ANAB
$1.58B
– –
-9,300
Closed -$258K
BHC icon
92
Bausch Health
BHC
$2.58B
– –
-20,000
Closed -$221K
CRVS icon
93
Corvus Pharmaceuticals
CRVS
$1.12B
– –
-13,600
Closed -$282K
HCA icon
94
HCA Healthcare
HCA
$87.2B
– –
-4,262
Closed -$379K
JNJ icon
95
Johnson & Johnson
JNJ
$618B
– –
-10,100
Closed -$1.26M
PRTA icon
96
Prothena Corp
PRTA
$425M
– –
-14,600
Closed -$815K
REGN icon
97
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-1,300
Closed -$504K
VREX icon
98
Varex Imaging
VREX
$472M
– –
-42,500
Closed -$1.43M
XENE icon
99
Xenon Pharmaceuticals
XENE
$6.06B
– –
-340,672
Closed -$1.36M
ZBH icon
100
Zimmer Biomet
ZBH
$18.2B
– –
-6,040
Closed -$716K
1 2 3
4
5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Endurant Capital Management held 110 positions worth $354M, up 14% from $311M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Endurant Capital Management deployed $21.7M of net new capital in Q2 2017, opening 22 new positions and adding to 38 existing holdings. Its largest new stake was Dentsply Sirona: 97,400 shares worth $6.32M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Hologic, an estimated $4.46M trimmed.

  • Endurant Capital Management's largest Q2 2017 buy was Dentsply Sirona: 97,400 shares worth $6.32M.
  • Endurant Capital Management added most to McKesson in Q2 2017, an estimated $9.24M increase.
  • Endurant Capital Management's biggest Q2 2017 reduction was Hologic, cutting an estimated $4.46M.
  • Endurant Capital Management fully exited CATALENT, INC. in Q2 2017, selling an estimated $8.25M.
  • Endurant Capital Management's ten largest holdings make up 34% of its $354M portfolio in Q2 2017.
  • Endurant Capital Management opened 22 new positions and closed 18 in Q2 2017.
  • Endurant Capital Management's portfolio value rose 14% quarter-over-quarter to $354M.

Based on Endurant Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.